Current and historical daily PE Ratio for Soligenix Inc (
) from 2007 to May 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Soligenix stock (STU:DOA) PE ratio as of May 23 2024 is 0.
More Details
Soligenix Inc (STU:DOA) PE Ratio (TTM) Chart
Soligenix Inc (STU:DOA) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1242
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Soligenix PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-25 | At Loss |
| 2024-02-26 | At Loss | 2023-12-22 | At Loss |
| 2024-02-23 | At Loss | 2023-12-21 | At Loss |
| 2024-02-22 | At Loss | 2023-12-20 | At Loss |
| 2024-02-21 | At Loss | 2023-12-19 | At Loss |
| 2024-02-20 | At Loss | 2023-12-18 | At Loss |
| 2024-02-19 | At Loss | 2023-12-15 | At Loss |
| 2024-02-16 | At Loss | 2023-12-14 | At Loss |
| 2024-02-15 | At Loss | 2023-12-13 | At Loss |
| 2024-02-14 | At Loss | 2023-12-12 | At Loss |
| 2024-02-13 | At Loss | 2023-12-11 | At Loss |
| 2024-02-12 | At Loss | 2023-12-08 | At Loss |
| 2024-02-09 | At Loss | 2023-12-07 | At Loss |
| 2024-02-08 | At Loss | 2023-12-06 | At Loss |
| 2024-02-07 | At Loss | 2023-12-05 | At Loss |
| 2024-02-06 | At Loss | 2023-12-04 | At Loss |
| 2024-02-05 | At Loss | 2023-12-01 | At Loss |
| 2024-02-02 | At Loss | 2023-11-30 | At Loss |
| 2024-02-01 | At Loss | 2023-11-29 | At Loss |
| 2024-01-31 | At Loss | 2023-11-28 | At Loss |
Soligenix Inc (STU:DOA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Soligenix Inc
NAICS : 325412
SIC : 2834
ISIN : US8342233074
Description
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers